Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...
Offering a Sense of Hope for Diffuse Large B-cell Lymphoma The Evolving Role of Bispecific Antibodies in Diffuse Large B-cell Lymphoma ...
Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...
The big question in administration of bispecific antibodies these days is how quickly they can move to the outpatient setting ...
BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...
Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...
In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...
– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results